Overview

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborator:
Novartis Pharmaceuticals
Treatments:
Peginterferon alfa-2a
Ribavirin